Anagrelide: 20 years later (Q37357291)

19 August 2017

1 reference

title

Anagrelide: 20 years later (English)

1 reference

19 August 2017

Ashkan Emadi

1

1 reference

19 August 2017

Jerry L Spivak

series ordinal

2

1 reference

19 August 2017

publication date

1 January 2009

1 reference

Expert Review of Anticancer Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

37-50

1 reference

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Disposition of anagrelide, an inhibitor of platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The effects of anagrelide on human megakaryocytopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Measurements of in vivo megakaryocytopoiesis: studies in nonhuman primates and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide: A New Drug for Treating Thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Long-term use of anagrelide in young patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide treatment in 52 patients with chronic myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide: what was new in 2004 and 2005?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Severe hypersensitivity pneumonitis associated with anagrelide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Renal tubular injury associated with anagrelide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Historical review: megakaryopoiesis and thrombopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The biogenesis of platelets from megakaryocyte proplatelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Roads to polyploidy: the megakaryocyte example

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Mechanisms of organelle transport and capture along proplatelets during platelet production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The molecular mechanisms that control thrombopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Incidence and etiology of thrombocytosis in an adult Turkish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Thrombocytosis in adults: analysis of 777 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Essential thrombocythemias. Clinical evolutionary and biological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

A long-term retrospective study of young women with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Management of the myeloproliferative disorders : distinguishing data from dogma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Phenotype and genotype in the myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

How I treat patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

No treatment for low-risk thrombocythaemia: results from a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Risk-adapted therapy in essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Treatment of essential thrombocythemia with special emphasis on leukemogenic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Multiple skin cancers associated with hydroxyurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Oral squamous cell carcinoma during long-term treatment with hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

The mutagenic activity of hydroxyurea in Chlamydomonas reinhardi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Fertility, pregnancy and the management of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Interferon alpha in the treatment of polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Current status of antifibrinolytic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

Anagrelide: a review of its use in the management of essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.37

21 January 2018

Identifiers

DOI

10.1586/14737140.9.1.37

1 reference

release_gaj57l2xevb7dd4p5ia62t67iy

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gaj57l2xevb7dd4p5ia62t67iy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference